ASX Announcements

4-Apr-2024	Tour de Cure Grant for Brain Cancer Research

27-Feb-2024	Appendix 4D and Half Year 2024 Financial Report

13-Feb-2024	Noxopharm extends Hudson Institute strategic partnership

22-Jan-2024	December 2023 Quarterly Activities Report and Appendix 4C

18-Dec-2023	Change of Director's Interest Notice - GM

18-Dec-2023	Notification of cessation of securities - NOX

16-Nov-2023	Results of Meeting

16-Nov-2023	Noxopharm Enhances Cash Position via R&D Rebate

16-Nov-2023	Noxopharm 2023 AGM Corporate Presentation

16-Nov-2023	Noxopharm 2023 AGM Chair Address

27-Oct-2023	Unlisted Options Expiring on 16 December 2023

18-Oct-2023	mRNA Vaccine Enhancer Shows Inflammation Reduction

13-Oct-2023	September 2023 Activities Report and Appendix 4C

9-Oct-2023	Response to ASX Query

4-Oct-2023	US FDA grants Orphan Drug Designation for CRO-67

3-Oct-2023	Trading Halt

3-Oct-2023	Pause in Trading

28-Sep-2023	Latest CRO-67 data shows success in reducing cancer growth

28-Sep-2023	2023 AGM Notice of Meeting and Proxy

28-Sep-2023	2023 AGM Letter to Shareholders and Proxy

27-Sep-2023	Annual Report to shareholders

21-Sep-2023	Change of Director's Interest Notice - FB

18-Sep-2023	Change of Director's Interest Notice - FB

31-Aug-2023	Appendix 4E and Audited Financial Statements

31-Aug-2023	Appendix 4G and Corporate Governance Statement

24-Jul-2023	Notification of cessation of securities - NOX

14-Jul-2023	June 2023 Activities Report and Appendix 4C

5-Jul-2023	Upcoming Expiry of Listed Options (ASX Code NOXOA)

5-Jul-2023	Unlisted Options expiring on 23 July 2023

5-Jul-2023	Notification of cessation of securities - NOX

3-Jul-2023	Change of Director's Interest Notice - FB

29-Jun-2023	Change of Director's Interest Notice - FB

19-Jun-2023	Change of Director's Interest Notice - FB

19-Jun-2023	Change of Director's Interest Notice - BP

19-Jun-2023	Change of Director's Interest Notice - PM

19-Jun-2023	Details of Company Address

26-May-2023	IONIC Trial Abstract Published at ASCO

19-May-2023	Study results show new Sofra drug reduces inflammation

18-May-2023	Innovative Sofra research presented at European event

10-May-2023	Change of Director's Interest Notice - FB

8-May-2023	Upcoming Expiry of Listed Options (ASX Code NOXO)

4-May-2023	Change of Director's Interest Notice - FB

24-Apr-2023	March 2023 Quarterly Activities Report and Appendix 4C

6-Apr-2023	Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs

28-Mar-2023	Noxopharm Announces Novel mRNA Vaccine Enhancer

24-Feb-2023	Appendix 4D and Half Year 2023 Financial Report

22-Feb-2023	Noxopharm to Present Sofra Study at LUPUS 2023 Conference

27-Jan-2023	December 2022 Quarterly Activities Report and Appendix 4C

17-Jan-2023	DARRT-2 Trial Efficacy Phase to Commence

16-Dec-2022	NOX Pipeline Boosted by $1.5M Grant to Hudson Institute

15-Dec-2022	Change of Director's Interest Notice - FB

15-Dec-2022	Notification of cessation of securities - NOX

6-Dec-2022	Federal Innovation Connections Grant Awarded

2-Dec-2022	IONIC Trial Progresses as Veyonda Passes Safety Milestone

21-Nov-2022	Notification of cessation of securities - NOX

17-Nov-2022	Constitution

17-Nov-2022	Results of Meeting

17-Nov-2022	Noxopharm 2022 AGM Corporate Presentation

17-Nov-2022	Noxopharm AGM 2022 Chair's Address

16-Nov-2022	CEP-2 Safety Milestone Shows Veyonda Progress

10-Nov-2022	Noxopharm Enhances Cash Position via R&D Rebate

25-Oct-2022	Change in substantial holding

21-Oct-2022	September 2022 Quarterly Activities Report and Appendix 4C

18-Oct-2022	2022 AGM Notice of Meeting and Proxy

18-Oct-2022	2022 AGM Letter to Shareholders and Proxy

7-Oct-2022	Unlisted Options Expiring on 21 November 2022

26-Sep-2022	Noxopharm 2022 Annual Report

20-Sep-2022	Final Director's Interest Notice - GK

19-Sep-2022	Resignation of Dr Graham Kelly as Non-Executive Director

14-Sep-2022	Novel Dual-cell Therapy Results in Pancreatic Cancer

2-Sep-2022	Response to ASX Price Query (Correction to ASX Ticker)

2-Sep-2022	Response to ASX Price Query

25-Aug-2022	Appendix 4E and Audited Financial Statements

25-Aug-2022	Appendix 4G and Corporate Governance Statement

16-Aug-2022	Noxopharm & UNSW Pancreatic Cancer Research at US Conference

9-Aug-2022	CEP-2 Trial Passes Safety Milestone

2-Aug-2022	DARRT-2 Trial Safety Milestone and European Site Activated

27-Jul-2022	June 2022 Quarterly Activities Report and Appendix 4C

5-Jul-2022	Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial

22-Jun-2022	$1.45M Grant to Hudson Institute for Noxopharm Collaboration

14-Jun-2022	Hudson Institute Collaboration Secures mRNA Victoria Acceleration Fund Grant

7-Jun-2022	Noxopharm Corporate Presentation

27-May-2022	Veyonda Abstract Published at ASCO Annual Meeting 2022

28-Apr-2022	March 2022 Quarterly Activities Report and Appendix 4C

22-Mar-2022	Orphan Drug Designation Granted to Noxopharm by US FDA

28-Feb-2022	First Patient Treated in CEP-2 Sarcoma Trial

21-Feb-2022	Appendix 4D and Half Year 2022 Financial Report

1-Feb-2022	Initial Director's Interest Notice - GM

27-Jan-2022	December 2021 Quarterly Activities Report and Appendix 4C

10-Jan-2022	Noxopharm Presents at H.C. Wainwright BioConnect Conference

7-Jan-2022	Noxopharm Receives A$5.865M R & D Tax Rebate

5-Jan-2022	Noxopharm Announces Leadership Transition

14-Dec-2021	Noxopharm DARRT-2 Cancer Trial Update

2-Dec-2021	Notification of cessation of securities - NOX

2-Dec-2021	Change of Director's Interest Notice - GK

17-Nov-2021	Noxopharm Annual General Meeting Results

17-Nov-2021	Licencing Deal Expands Noxopharm Drug Opportunities

17-Nov-2021	Noxopharm 2021 AGM Corporate Presentation

17-Nov-2021	Noxopharm 2021 AGM Chairmans Address

16-Nov-2021	Retraction of Grant Announcement

15-Nov-2021	Trading Halt

15-Nov-2021	Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial

4-Nov-2021	DARRT-2 Trial Commences in the U.S.

29-Oct-2021	Unlisted Options Expiring on 30 November 2021

26-Oct-2021	Veyonda and Opdivo IONIC Study First Patient Dosed

25-Oct-2021	Patent Granted for Veyonda and Low Dose Chemotherapy

20-Oct-2021	Jobkeeper s323DB Notice

15-Oct-2021	2021 AGM Notice of Meeting and Proxy

15-Oct-2021	2021 AGM Letter to Shareholders and Proxy

14-Oct-2021	September 2021 Quarterly Activities Report and Appendix 4C

29-Sep-2021	Cleansing Notice

29-Sep-2021	Application for quotation of securities - NOX

27-Sep-2021	Veyonda Achieves Important U.S. Patent Claims

10-Sep-2021	Noxopharm 2021 Annual Report

9-Sep-2021	Noxopharm Updated Corporate Presentation

30-Aug-2021	Change of Registered Office and Principal Place of Business

26-Aug-2021	Appendix 4E and Audited Financial Statements

26-Aug-2021	Appendix 4G and Corporate Governance Statement

23-Aug-2021	Cleansing Notice

23-Aug-2021	Application for quotation of securities - NOX

23-Aug-2021	Pre-clinical Data Supports a Role for Veyonda in COVID-19

23-Aug-2021	NOXCOVID Program to Expand After Positive Phase 1 Results

19-Aug-2021	Trading Halt

13-Aug-2021	Cleansing Notice

13-Aug-2021	Application for quotation of securities - NOX

11-Aug-2021	Additional Information on US NCI Collaboration

9-Aug-2021	NOX and US Govt Peak Cancer Agency Announce Collaboration

5-Aug-2021	Veyonda Survival Advantage in LuPSMA Therapy Confirmed

27-Jul-2021	June 2021 Quarterly Activities Report and Appendix 4C

1-Jul-2021	DARRT-2 Study Receives IND Approval from FDA

29-Jun-2021	Noxopharm Secures Key European Patent Allowance for Veyonda

28-Jun-2021	Noxopharm Corporate Presentation

21-Jun-2021	Cleansing Notice

21-Jun-2021	Application for quotation of securities - NOX

10-Jun-2021	DARRT-2 Study Update and Clarification

8-Jun-2021	The Noxopharm Newsletter June 2021

4-Jun-2021	Noxopharm Set to Benefit From Novartis ASCO Data

31-May-2021	Becoming a substantial holder

31-May-2021	Change of Director's Interest Notice - FB

31-May-2021	Change of Director's Interest Notice - BP

31-May-2021	Cleansing Notice

31-May-2021	Appendix 2A

31-May-2021	Appendix 3G

31-May-2021	Noxopharm Extraordinary General Meeting Results

31-May-2021	New Independent Trial Data Supports Potential of Veyonda

13-May-2021	Noxopharm to Present to Share Cafe Hidden Gems Webinar

12-May-2021	NOXCOVID Trial Achieves Full Enrolment

7-May-2021	Cleansing Notice

7-May-2021	Appendix 2A

7-May-2021	Veyonda FDA Approved Trial to Commence

4-May-2021	Securities Trading Policy

30-Apr-2021	Cleansing Notice

30-Apr-2021	Appendix 2A

30-Apr-2021	Change of Director's Interest Notice - BP

30-Apr-2021	Lapsing of Unlisted Options

30-Apr-2021	Publications Positive Review of Veyonda in Chemotherapy

29-Apr-2021	Notice of General Meeting/Proxy Form

27-Apr-2021	March Quarterly Activities Report and Appendix 4C

22-Apr-2021	Veyonda Showing Potential to Prevent Cytokine Storm

22-Apr-2021	Pause in Trading

12-Apr-2021	Cleansing Notice

12-Apr-2021	Appendix 2A

6-Apr-2021	Veyonda Patent Lodged for Major Septic Shock Opportunity

29-Mar-2021	Corporate Presentation for Switzer Virtual Investor Day

19-Mar-2021	Noxopharm IONIC Immuno-Oncology Trial Commences

16-Mar-2021	ASX Small-Mid Cap Conference Corporate Presentation

8-Mar-2021	NOXCOVID Trial Advances to Final Stage

5-Mar-2021	Noxopharm Presents to H.C. Wainwright Global Conference

4-Mar-2021	Cleansing Notice

4-Mar-2021	Appendix 2A

2-Mar-2021	Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate

1-Mar-2021	Proposed issue of Securities - NOX

1-Mar-2021	Lapsing of Unlisted Options and Shortfall Shares

1-Mar-2021	Change of Director's Interest Notice - PM

26-Feb-2021	Change in substantial holding

26-Feb-2021	Change of Director's Interest Notice - GK

26-Feb-2021	Cleansing Notice

26-Feb-2021	Appendix 2A

24-Feb-2021	Company Announcement Regarding Appendix 3Y Disclosures

24-Feb-2021	Change in substantial holding

24-Feb-2021	Change of Director's Interest Notice - GK

23-Feb-2021	Noxopharm Updated Corporate Presentation February-March 2021

19-Feb-2021	Option Underwriting Agreement to Secure Funds

19-Feb-2021	Cleansing Notice

19-Feb-2021	Appendix 2A

16-Feb-2021	Noxopharm CEO Letter to Shareholders February 2021

16-Feb-2021	Appendix 4D and Half Year Financial Report

15-Feb-2021	Cleansing Notice

15-Feb-2021	Appendix 2A

15-Feb-2021	LuPIN Survival Outcome Confirmed by Conference Presentation

9-Feb-2021	Major Survival Benefit in Prostate Cancer Patients Announced

5-Feb-2021	Cleansing Notice

5-Feb-2021	Appendix 2A

3-Feb-2021	Cleansing Notice

3-Feb-2021	Appendix 2A

28-Jan-2021	Noxopharm To Present to ShareCafe Hidden Gems Webinar

25-Jan-2021	Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C

22-Jan-2021	Cleansing Notice

22-Jan-2021	Appendix 2A

13-Jan-2021	NOXCOVID Study Advances

12-Jan-2021	Unlisted Options Expiring 28 February 2021

6-Jan-2021	Noxopharm Shareholder Update 2021

23-Dec-2020	Federal Government Approved Future Overseas R&D Expenditure

15-Dec-2020	Cleansing Notice

15-Dec-2020	Appendix 2A

15-Dec-2020	Change of Director's Interest Notice - BP

15-Dec-2020	Change of Director's Interest Notice - FB

15-Dec-2020	Appendix 3G

11-Dec-2020	December Investor Webinar Recording

10-Dec-2020	Change in substantial holding

10-Dec-2020	Cleansing Notice

10-Dec-2020	Appendix 2A

8-Dec-2020	Noxopharm Corporate Presentation December Investor Webinar

7-Dec-2020	Pre-Clinical Breakthrough Discovery Set to Expand Pipeline

4-Dec-2020	Noxopharm December Investor Webinar Details

3-Dec-2020	Cleansing Statement

3-Dec-2020	Proposed issue of Securities - NOX

3-Dec-2020	Noxopharm Completes A$23m Placement to Fund Clinical Studies

1-Dec-2020	Appendix 2A

1-Dec-2020	Trading Halt

27-Nov-2020	Change of Director's Interest Notice - PM

27-Nov-2020	Lapsing of Unlisted Options

18-Nov-2020	Change of Director's Interest Notice - GK

18-Nov-2020	Cleansing Notice

18-Nov-2020	Appendix 2A

18-Nov-2020	Appendix 3G

18-Nov-2020	Further Independent Support for Veyonda as a Major I-O Drug

17-Nov-2020	Noxopharm Annual General Meeting Results

17-Nov-2020	Noxopharm 2020 AGM Corporate Update

17-Nov-2020	2020 AGM Chairman's Address

13-Nov-2020	Independent Discovery Validates DARRT Cancer Therapy

9-Nov-2020	Veyonda To Be Tested In Combination With Opdivo In Trial

5-Nov-2020	Dedicated Septic Shock Company Established

5-Nov-2020	NOXCOVID Study Cleared To Expand

3-Nov-2020	2020 Annual General Meeting Reminder

26-Oct-2020	Cleansing Notice

26-Oct-2020	Appendix 2A

26-Oct-2020	First Two Cohorts Enrolled in NOXCOVID Study

15-Oct-2020	Noxopharm September 2020 Quarterly Activities Report & Appendix 4C

14-Oct-2020	Cover Letter and Proxy Form - Annual General Meeting

14-Oct-2020	Notice of Annual General Meeting and Proxy Form

12-Oct-2020	LuPIN Study Achieves Final Patient Treatment

9-Oct-2020	Noxopharm CMO Discusses the NOXCOVID trial

9-Oct-2020	Unlisted Options Expiring 27 November 2020

9-Oct-2020	Cleansing Notice

9-Oct-2020	Appendix 2A

6-Oct-2020	Noxopharm Loan Terms Amended to Benefit Company

2-Oct-2020	First COVID-19 Patient Treated in Veyonda Study

21-Sep-2020	Noxopharm Corporate Presentation September 2020

18-Sep-2020	Noxopharm Appoints US Corporate Advisory and Consulting Firm

17-Sep-2020	Notification of Date of 2020 Annual General Meeting

15-Sep-2020	Annual Report to shareholders

15-Sep-2020	Appendix 4G and Corporate Governance Statement

9-Sep-2020	Noxopharm Appoints New Chair

8-Sep-2020	Global CRO To Execute DARRT-2 Prostate Cancer Study

1-Sep-2020	Veyonda COVID-19 Study Approved For Immediate Start

31-Aug-2020	Final Director's Interest Notice - ID

31-Aug-2020	Appendix 4E and Audited Financial Statements FY2020

31-Aug-2020	Appendix 4G and Corporate Governance Statement

31-Aug-2020	Noxopharm Announces Board Changes

14-Aug-2020	Appendix 2A - Shares

14-Aug-2020	Cleansing Notice

14-Aug-2020	Appendix 2A - Underwriter Options

14-Aug-2020	Results of Meeting

14-Aug-2020	Noxopharm August 2020 EGM Corporate Presentation

11-Aug-2020	Peer-Reviewed Publication Strengthens Case For Veyonda

6-Aug-2020	Noxopharm Extraordinary General Meeting Reminder

29-Jul-2020	Noxopharm June 2020 Quarterly Activities Report & Appendix 4C

24-Jul-2020	Change of Director's Interest Notice - FB

24-Jul-2020	Notice of Contravention of Listing Rule 10.11

23-Jul-2020	Noxopharm Discusses Converting Cold to Hot Cancer Tumours

22-Jul-2020	Receipt of cash payment for collateral shares

20-Jul-2020	Data Shows Idronoxil Holds Key to Problem of COLD Cancers

14-Jul-2020	Noxopharm July 2020 Newsletter Released

14-Jul-2020	Letter to Shareholders - Extraordinary General Meeting

14-Jul-2020	Notice of Extraordinary General Meeting/Proxy Form

8-Jul-2020	Corporate Presentation for the Reach Markets Virtual Event

3-Jul-2020	Ceasing to be a substantial holder

29-Jun-2020	Change of Director's Interest Notice - FB

22-Jun-2020	Change in substantial holding - amended

22-Jun-2020	Change in substantial holding

22-Jun-2020	Noxopharm Chair Letter to Shareholders

19-Jun-2020	COVID-19 Trial Program to Commence in Europe

18-Jun-2020	Change in substantial holding

18-Jun-2020	Change in substantial holding

18-Jun-2020	Change of Director's Interest Notice - BP

18-Jun-2020	Change of Director's Interest Notice - FB

18-Jun-2020	Change of Director's Interest Notice - PM

18-Jun-2020	Change of Director's Interest Notice - GK

18-Jun-2020	Appendix 2A - shares

18-Jun-2020	Appendix 2A - options

15-Jun-2020	Pro-rata Non-Renounceable Rights Issue Fully Allocated

9-Jun-2020	Rights Issue Close Date

5-Jun-2020	Webcast Overview of ASCO 2020 Annual Meeting NOX Posters

4-Jun-2020	Change of Director's Interest Notice - PM

4-Jun-2020	Change of Director's Interest Notice - ID

1-Jun-2020	Appendix 3G Adjustment to Option Exercise Prices

1-Jun-2020	ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer

28-May-2020	Listing Rule 6.22.2 Adjustment to Option Exercise Prices

22-May-2020	Proposed issue of Securities - NOX

21-May-2020	Despatch of Pro Rata Entitlement Offer Documents

19-May-2020	FDA allows Veyonda Pre-IND Submission for COVID-19

14-May-2020	Noxopharm ASCO Abstracts Live

13-May-2020	Appendix 2A

13-May-2020	Entitlement Offer Prospectus

13-May-2020	Entitlement Offer - Letter to Optionholders

13-May-2020	Entitlement Offer - Letter to Ineligible Shareholders

13-May-2020	Entitlement Offer - Letter to Eligible Shareholders

13-May-2020	Proposed issue of Securities - NOX

13-May-2020	$7.9 Million Fully Underwritten Entitlement Offer Announced

8-May-2020	Initial Director's Interest Notice - FB

8-May-2020	Appointment of New Board Member

7-May-2020	Trading Halt

1-May-2020	Change in substantial holding

1-May-2020	Change in substantial holding

30-Apr-2020	Noxopharm March 2020 Quarterly Report & Appendix 4C

30-Apr-2020	Abscopal Responses Achieved in Prostate Cancer

23-Apr-2020	Pipeline Expands With Potential New Brain Cancer Treatment

21-Apr-2020	Approval to be sought for COVID-19 Clinical Study in U.S.

20-Apr-2020	Receipt of cash payment for collateral shares

7-Apr-2020	Noxopharm trial data to be presented at ASCO 2020

2-Apr-2020	Updated Noxopharm Virtual Roadshow Corporate Presentation

1-Apr-2020	Noxopharm Investigating Potential COVID-19 Treatment

31-Mar-2020	Noxopharm Virtual Roadshow Corporate Presentation

26-Mar-2020	Initial Director's Interest Notice

26-Mar-2020	Appointment of New Board Member

17-Mar-2020	Veyonda Awarded First Allowed Patent Application

13-Mar-2020	Veyonda Clinical Program Update and Guidance

3-Mar-2020	LuPIN Prostate Cancer Trial Fully Recruited

27-Feb-2020	Noxopharm Corporate Presentation February 2020

25-Feb-2020	Half Year Accounts and Chairman Letter

21-Feb-2020	Section 708 Certificate

21-Feb-2020	Appendix 2A

21-Feb-2020	FDA grants IND approval to Veyonda

18-Feb-2020	Termination of Convertible Loan

18-Feb-2020	Section 708 Certificate

18-Feb-2020	Appendix 2A

18-Feb-2020	Noxopharm Alliance With GenesisCare

14-Feb-2020	Proposed issue of Securities - NOX

14-Feb-2020	$8.1M Financing & Re-Set of Capital Structure

14-Feb-2020	Pronounced survival benefit in LuPIN interim trial data

12-Feb-2020	Trading Halt

11-Feb-2020	LuPIN interim trial data to be presented at ASCO GU 2020

6-Feb-2020	Lapsing of Unlisted Options

31-Jan-2020	Noxopharm December 2019 Quarterly Activities Report & Appendix 4C

29-Jan-2020	Noxopharm Non-Deal Roadshow Presentation

20-Jan-2020	Appendix 3B

16-Jan-2020	Listing of Nyrada Inc. spin-off on ASX

16-Jan-2020	Becoming a substantial holder for NYR

15-Jan-2020	Noxopharm Corporate Presentation

27-Dec-2019	Ceasing to be a substantial holder

23-Dec-2019	Change of Director's Interest Notice - GK

23-Dec-2019	Section 708 Certificate

23-Dec-2019	Appendix 3B

20-Dec-2019	DARRT-1 Clinical Data Webinar

17-Dec-2019	Nyrada IPO Offer Fully Subscribed

13-Dec-2019	Unlisted Options Expiring 18 January 2020

9-Dec-2019	Lodgement of Nyrada Inc Supplementary Prospectus

4-Dec-2019	Nyrada Inc Initial Public Offering Opens

3-Dec-2019	Section 708 Certificate - Notes

3-Dec-2019	Section 708 Certificate

3-Dec-2019	Appendix 3B

3-Dec-2019	AU$2.4m Increase to Funding Agreement

3-Dec-2019	Section 708 Certificate

3-Dec-2019	Appendix 3B

2-Dec-2019	Positive DARRT-1 Data in Late-Stage Prostate Cancer

28-Nov-2019	Trading Halt

26-Nov-2019	Lodgement of Nyrada Inc Prospectus - Initial Public Offering

26-Nov-2019	Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive

20-Nov-2019	Constitution

20-Nov-2019	Results of Meeting

20-Nov-2019	Noxopharm 2019 AGM Corporate Presentations

12-Nov-2019	DARRT-1 Interim Data Presented To Conference

12-Nov-2019	LuPIN Data Being Presented To Conference

6-Nov-2019	Appointment of Chief Commercial Officer

30-Oct-2019	Noxopharm October 2019 Newsletter

30-Oct-2019	Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019

28-Oct-2019	Dr Graham Kelly to Assume CEO Role

25-Oct-2019	Appendix 3B

25-Oct-2019	Section 708 Certificate

22-Oct-2019	NOX and Nyrada TechKnow Invest Roadshow Presentations

21-Oct-2019	Durable Anti-Cancer Effect Confirmed in DARRT-1 Study

18-Oct-2019	Notice of 2019 Annual General Meeting & Proxy Form

18-Oct-2019	Potential Fundamental Change in Treatment of Brain Cancer

16-Oct-2019	New Executive Appointments and Board Change

16-Oct-2019	Final Director's Interest Notice

2-Oct-2019	Noxopharm 2019 Annual General Meeting Details

2-Oct-2019	FNN Interview: The LuPIN trial with Veyonda in prostate cancer

30-Sep-2019	Further Review Shows Major Clinical Benefits from Veyonda

26-Sep-2019	Corporate Governance Statement - Appendix 4G

26-Sep-2019	Corporate Governance Statement

26-Sep-2019	Section 708 Certificate

26-Sep-2019	Appendix 3B

26-Sep-2019	Annual Report to Shareholders

24-Sep-2019	Departure of Dr Van Wyk

17-Sep-2019	Veyonda and Radiotherapy Profiled at Key Oncology Meeting

16-Sep-2019	Results of Meeting

16-Sep-2019	NOX EGM Chairman's Address and Presentation

12-Sep-2019	CHANGE OF DIRECTOR'S INTEREST NOTICE - GK

10-Sep-2019	CHANGE OF DIRECTOR'S INTEREST NOTICE - GK

29-Aug-2019	Appendix 4E and Audited Financial Statements FY19

28-Aug-2019	Addendum to Notice of Extraordinary General Meeting

28-Aug-2019	More Evidence that Veyonda Enhances RT in Prostate Cancer

23-Aug-2019	NOX Receives FY19 Federal Government R&D Tax Rebate

23-Aug-2019	Appendix 3B

23-Aug-2019	Cleansing Statement

21-Aug-2019	Pre-Clinical Evidence Confirms Veyonda Abscopal Effect

15-Aug-2019	Lead Manager Appointed for Proposed Nyrada IPO

12-Aug-2019	Notice of Extraordinary General Meeting/Proxy Form

9-Aug-2019	Noxopharm Corporate Update Interview

7-Aug-2019	Noxopharm August 2019 Corporate Presentation

2-Aug-2019	NOX Releases Initial Newsletter for Nyrada Subsidiary

29-Jul-2019	Appendix 4C - Quarterly Report for the quarter ending June 30, 2019

25-Jul-2019	Appendix 3B

25-Jul-2019	Section 708 Certificate

23-Jul-2019	Appendix 3B

23-Jul-2019	Section 708 Certificate

19-Jul-2019	Initial Director's Interest Notice

19-Jul-2019	Final Director's Interest Notice

19-Jul-2019	NOX Announces AU$26 Million Funding Facility

17-Jul-2019	NOX Releases Latest Newsletter

16-Jul-2019	Board Changes Ahead of Corporate Growth

2-Jul-2019	LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019

26-Jun-2019	Conference Hears of Positive Interim Data from LuPIN Trial

7-Jun-2019	NOX Subsidiary, Nyrada Inc, Receives R&D Rebate

6-Jun-2019	Noxopharm Corporate Presentation June 2019

30-May-2019	DARRT-1 Study Fully Enrolled

23-May-2019	Promising Data Leads to Expansion of LuPIN Trial

20-May-2019	LuPIN Trial Demonstrates High Rates of Response

8-May-2019	Change of Director's Interest Notice - GK

8-May-2019	Appendix 3B

2-May-2019	DARRT Treatment Has Lasting Disease Control at Six Months

29-Apr-2019	Veyonda and Immuno-Oncology Effect Explained

26-Apr-2019	Appendix 4C - Quarterly

23-Apr-2019	Change in Noxopharm Limited Board Structure

16-Apr-2019	Idronoxil Confirmed as New Immuno-Oncology Drug

10-Apr-2019	Veyonda Chemotherapy Enhancement Program to be Expanded

8-Apr-2019	Securities to be released from Voluntary Escrow

5-Apr-2019	Updated Top 20 shareholder List

25-Mar-2019	Appendix 3B

25-Mar-2019	Section 708 Certificate

21-Mar-2019	Becoming a substantial holder

19-Mar-2019	KZA: Kazia sells stake in Noxopharm

6-Mar-2019	NOX provides update to Nyrada Note Holders

5-Mar-2019	New Corporate Presentation Released

21-Feb-2019	Noxopharm to expedite Veyonda Clinical Program

21-Feb-2019	Appendix 4D and Half Year Accounts

14-Feb-2019	Change of Director's Interest Notice - GK

6-Feb-2019	FNN interview with Nox Chief Medical Officer on Interim Data

6-Feb-2019	Veyonda and Radiotherapy Delivers Clinical Benefits

1-Feb-2019	Appendix 3B

29-Jan-2019	Appendix 4C - quarterly report for the quarter ended December 31, 2018

14-Jan-2019	Principal Investigator Discusses LuPIN-1 Study

21-Dec-2018	Change of Director's Interest Notice - GK

21-Dec-2018	Section 708 Certificate

21-Dec-2018	Appendix 3B

20-Dec-2018	NOX Receives $3.26M Federal Govt R&D Rebate

11-Dec-2018	DARRT-1 study advancing on basis of positive clinical data

29-Nov-2018	NOX announces Positive Data from CEP-1 Study of Veyonda

21-Nov-2018	Initial Director's Interest Notice

21-Nov-2018	Results of Meeting

21-Nov-2018	Appointment of Mr John Moore as Non-Executive Director

21-Nov-2018	NOX 2018 AGM Presentations

20-Nov-2018	NOX 2018 AGM Information

13-Nov-2018	NOX to Present Clinical Data at COSA Annual Meeting

8-Nov-2018	Corporate Presentation

26-Oct-2018	Appendix 4C - Quarterly report for the quarter ended September 30, 2018

22-Oct-2018	NOX makes key executive appointment

5-Oct-2018	Notice of Annual General Meeting & Proxy Form

4-Oct-2018	Noxopharm Releases Report on Key Progress of Subsidiary

2-Oct-2018	Section 708 Certificate

2-Oct-2018	Appendix 3B

28-Sep-2018	Change of Director's Interest Notice - PM

28-Sep-2018	Section 708 Certificate

28-Sep-2018	Appendix 3B

28-Sep-2018	Change of Registry Address: Automic P/L - Sydney Office

27-Sep-2018	Annual Report to shareholders

27-Sep-2018	Corporate Governance Statement - Appendix 4G

27-Sep-2018	Corporate Governance Statement - 2018

24-Sep-2018	NOX Subsidiary Announces Important Drug Discovery

5-Sep-2018	NOX to support expanded LuPIN study

30-Aug-2018	Appendix 4E and Audited Financial Statements

27-Aug-2018	Nyrada-Key progress with cholesterol-lowering drug candidate

20-Aug-2018	VEYONDA - Registered Trade Mark for NOX66

9-Aug-2018	Change of Director's Interest Notice - GK

9-Aug-2018	Change of Director's Interest Notice - PM

9-Aug-2018	Change of Director's Interest Notice - ID

9-Aug-2018	Appendix 3B

8-Aug-2018	Interim NOX66 Radiotherapy Clinical Data

30-Jul-2018	Appendix 4C- Quarterly report for the quarter ended June 30, 2018

10-Jul-2018	Securities to be released from Escrow

9-Jul-2018	Release of DARRT-1 Preliminary Safety Data

5-Jul-2018	Pre-Clinical data confirms Radio-Enhancing potential

7-Jun-2018	Noxopharm Corporate Presentation for Public Briefing

5-Jun-2018	End-of-Study Clinical Data shows benefit of NOX66

31-May-2018	Noxopharm 2018 Mid-Year Investor Briefings

28-May-2018	Section 708 Certificate

28-May-2018	Appendix 3B

22-May-2018	NOX to present at American Society of Clinical Oncology

21-May-2018	Change in substantial holding

21-May-2018	Securities to be released from Voluntary Escrow

21-May-2018	Section 708 Certificate

21-May-2018	Appendix 3B

18-May-2018	Noxopharm 2018 Mid-Year Investor Briefings

15-May-2018	Results of Meeting

7-May-2018	NOX CEO interview updates the company's current R&D program

3-May-2018	NOX CEO interview on near complete NOX66 chemotherapy trial

27-Apr-2018	NOX CEO interview on Radiotherapy Clinical Programs

27-Apr-2018	Appendix 4C - quarterly

17-Apr-2018	St Vincent's Hospital study passes first milestone

9-Apr-2018	Notice of Extraordinary General Meeting / Proxy Form

6-Apr-2018	Change in substantial holding

6-Apr-2018	Change in substantial holding

5-Apr-2018	DARRT-1 Clinical Study commences

5-Apr-2018	NOX Mid-Year Briefings

29-Mar-2018	Section 708 Certificate

29-Mar-2018	Appendix 3B

23-Mar-2018	NOX raises $10.8 M to advance clinical program

21-Mar-2018	Trading Halt

21-Mar-2018	Evidence of Abscopal Responses in Patients

12-Mar-2018	Corporate Presentation - Post Interim Clinical Data Release

9-Mar-2018	FNN Interview with Noxopharm CEO

6-Mar-2018	NOX Reports NOX66 Clinical Data

5-Mar-2018	Trading Halt

23-Feb-2018	Update accompanying Half Year Report

23-Feb-2018	Appendix 4D and Half Year Accounts

16-Feb-2018	NOX closes $4m capital raising for US subsidiary Nyrada Inc

31-Jan-2018	Appendix 4C - quarterly

25-Jan-2018	Section 708 Certificate

25-Jan-2018	Appendix 3B

18-Jan-2018	Section 708 Certificate

18-Jan-2018	Appendix 3B

17-Jan-2018	NOX receives FY17 R&D Tax Rebate

27-Dec-2017	Kazia Therapeutics Ltd and Noxopharm Ltd

21-Dec-2017	EOY Guidance on 2018 NOX66 Clinical Development Strategy

19-Dec-2017	Section 708 Certificate

19-Dec-2017	Appendix 3B

14-Dec-2017	Response to ASX Price Query

12-Dec-2017	Appendix 3B

11-Dec-2017	Change of Registered Office

7-Dec-2017	Section 708 Certificate

7-Dec-2017	Appendix 3B

6-Dec-2017	NOX Open Briefing Corporate Presentation

4-Dec-2017	Compassionate use of NOX66 in Patients

1-Dec-2017	Nyrada Inc Opens Capital Raise - Memorandum Released

29-Nov-2017	Change of Director's Interest Notice - PM

29-Nov-2017	Change of Director's Interest Notice - ID

29-Nov-2017	Appendix 3B

29-Nov-2017	Webcast of NOX 2017 AGM

29-Nov-2017	NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model

28-Nov-2017	Invitation to Open Briefing

27-Nov-2017	Results of Meeting

27-Nov-2017	AGM Presentations

23-Nov-2017	Clarification of Incorrect Information

23-Nov-2017	Trading Halt

21-Nov-2017	NOX 2017 AGM Webcast

21-Nov-2017	Completion of Transfer of Shares to Nyrada Inc

20-Nov-2017	Promising Interim Clinical Data for NOX66

17-Nov-2017	Trading Halt

16-Nov-2017	1st Patient treated in Lupin Study at St Vincent's Hospital

15-Nov-2017	Section 708 Certificate

15-Nov-2017	Appendix 3B

13-Nov-2017	NOX making three presentations at COSA

7-Nov-2017	Section 708 Certificate

7-Nov-2017	Appendix 3B

6-Nov-2017	Results of Meeting

6-Nov-2017	EGM Presentations

3-Nov-2017	UNSW collaboration confirms drug designed for stroke victims

30-Oct-2017	Appendix 4C – Quarterly report for the quarter ended September 30, 2017

26-Oct-2017	Notice of Annual General Meeting/Proxy Form

26-Oct-2017	Annual Report to shareholders

23-Oct-2017	Update - General Meeting Agenda

19-Oct-2017	October 2017 Open Briefing Corporate Presentation

13-Oct-2017	Invitation to Open Briefing

4-Oct-2017	Establishment of Nyrada Inc. - Extraordinary General Meeting

27-Sep-2017	Australian NOX66 - Radiotherapy Study Opens

25-Sep-2017	Establishment of Nyrada Inc.

12-Sep-2017	Positive Clinical Outcomes for NOX66 at ESMO Conference

7-Sep-2017	Change in substantial holding

6-Sep-2017	Change in substantial holding

4-Sep-2017	Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice

4-Sep-2017	NOX CEO Interview explains recent Brain Cancer Announcement

31-Aug-2017	Appendix 4E and Audited Financial Statements

31-Aug-2017	Corporate Governance Statement - Appendix 4G

31-Aug-2017	Corporate Governance Statement

29-Aug-2017	Important Brain Cancer Findings for NOX66 Program

24-Aug-2017	Reinstatement to Official Quotation

24-Aug-2017	Noxopharm raises $5.5 million to advance clinical program

23-Aug-2017	Suspension from Official Quotation

21-Aug-2017	Trading Halt Request

21-Aug-2017	Trading Halt

8-Aug-2017	NOX Corporate Presentation ahead of Conference

31-Jul-2017	Appendix 4C - quarterly

27-Jul-2017	NOX Research Report prepared by APP Securities

25-Jul-2017	CEO Interview with FNN - Singapore and HK Roadshow

25-Jul-2017	New Corporate Presentation

6-Jul-2017	Noxopharm provides update on NOX66 Clinical Trial Program

19-Jun-2017	Idronoxil data provides hope to treat secondary brain cancer

5-Jun-2017	NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment

30-May-2017	New Corporate Presentation

29-May-2017	St Vincents Cancer Study to Commence-NOX66 and Radiotherapy

24-May-2017	NOX makes strategic commitment to treatment of rare cancers

18-May-2017	Noxopharm Mid Year Investor Briefings

2-May-2017	Market Guidance for Next Six Months

27-Apr-2017	Appendix 4C - quarterly

10-Apr-2017	FNN Interview with NOX CEO Explaining Idronoxil-C Discovery

10-Apr-2017	NOX Files Patent Application on 'Smart' Idronoxil

3-Apr-2017	Appendix 3B

27-Mar-2017	NOX and Monash Uni Collaboration Receives Federal Grant

16-Mar-2017	Noxopharm and UNSW combine on stroke project

10-Mar-2017	Gold Coast Qld Mid-Year Briefing Details

7-Mar-2017	Notification of Release of Restricted Securities Escrow

3-Mar-2017	NOX researching rare Abscopal Response

24-Feb-2017	Appendix 4D and Half Year Accounts

24-Feb-2017	NOX Presentation and Interview ASX The CEO Sessions

21-Feb-2017	ASX CEO Presentation Feb 2017 slides

15-Feb-2017	Upcoming Events and Presentations

3-Feb-2017	Change of Principal Place of Business

1-Feb-2017	Brain Cancer Study Commences

31-Jan-2017	First NOX66 Clinical Trial to Commence

30-Jan-2017	Appendix 4C – Quarterly report for the quarter ended 31 December 2016

16-Jan-2017	Appointment of New Company Secretary

9-Jan-2017	Appendix 3B

20-Dec-2016	Change in substantial holding

20-Dec-2016	Change of Director's Interest Notice - ID

20-Dec-2016	Change of Director's Interest Notice - GK

20-Dec-2016	Market Capitalisation - further update

20-Dec-2016	Appendix 3B

19-Dec-2016	Market Capitalisation Update

23-Nov-2016	Results of Meeting

23-Nov-2016	Breakthrough in Delivering Idronoxil into Brain

22-Nov-2016	Corporate Presentation Updated

22-Nov-2016	Corporate Presentation Providing Clinical Program Guidance

17-Nov-2016	Medical Advisors Appointed for Extensive Clinical Program

14-Nov-2016	Change in substantial holding DH

31-Oct-2016	Appendix 4C - quarterly

24-Oct-2016	Noxopharm 2016 AGM Sydney Briefing

21-Oct-2016	Annual Report to shareholders

20-Oct-2016	Corporate Presentation

3-Oct-2016	Appendix 4G

30-Sep-2016	Amendment to Preliminary Final Report

12-Sep-2016	Corporate Presentation for Roadshow

31-Aug-2016	Preliminary Final Report

25-Aug-2016	Change in substantial holding

22-Aug-2016	Change in substantial holding DH

22-Aug-2016	Noxopharm to Initiate Radiotherapy Clinical Studies

19-Aug-2016	Change of Director's Interest Notice - GK

10-Aug-2016	Becoming a substantial holder

10-Aug-2016	Becoming a substantial holder

10-Aug-2016	Becoming a substantial holder

10-Aug-2016	Initial Director's Interest Notice - PM

10-Aug-2016	Initial Director's Interest Notice - ID

10-Aug-2016	Initial Director's Interest Notice - GK

9-Aug-2016	Noxopharm Limited commences trading on ASX

8-Aug-2016	Performance Share Terms

8-Aug-2016	Option Terms

8-Aug-2016	Restricted Securities and Capital Structure

8-Aug-2016	Securities Trading Policy

8-Aug-2016	Financial Accounts

8-Aug-2016	Constitution

8-Aug-2016	ASX Market Release - Admission to Official List

8-Aug-2016	Appendix 1A & Information Form and Checklist

8-Aug-2016	Top 20 Holders

8-Aug-2016	Distribution Schedule

8-Aug-2016	Company's Admission Disclosures

8-Aug-2016	ASX Market Release - Pre-Quotation Disclosure

8-Aug-2016	Prospectus

8-Aug-2016	ASX Notice - Admission and Commencement of Quotation

Copyright © Noxopharm